ABBOTT LABORATORIES

原文(英語・SEC 10-K)ITEM 1. BUSINESS GENERAL DEVELOPMENT OF BUSINESS Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott’s* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation (Exact Sciences), which is expected to enable Abbott to enter the cancer diagnostics market. The acquisition is subject to customary closing conditions, including the approval of Exact Sciences shareholders and obtaining the required regulatory clearances. NARRATIVE DESCRIPTION OF BUSINESS Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products These products include a broad line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. These products are generally sold directly to wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and independent retailers from Abbott-owned distribution centers or public warehouses, depending on the market served. Certain products are co-marketed or co-promoted with, or licensed from, other companies. The principal products included in the broad therapeutic area portfolios of the Established Pharmaceutical Products segment are: • gastroenterology products, including CreonTM, for the treatment of pancreatic exocrine insufficiency associated with several underlying conditions, including cystic fibrosis and chronic pancreatitis; DuspatalTM and DicetelTM, for the treatment of irritable bowel syndrome or biliary spasm; HeptralTM, TransmetilTM, and SamyrTM, for the treatment of intrahepatic cholestasis (associated with liver disease) or depressive symptoms; and DuphalacTM, for regulation of the physiological rhythm of the colon; • women’s health products, including DuphastonTM, for the treatment of gynecological disorders; and FemostonTM, a hormone replacement therapy for postmenopausal women; • cardiovascular and metabolic products, including LipanthylTM and TriCorTM, for the treatment of dyslipidemia and diabetic retinopathy; OmacorTM, for the treatment of hypertriglyceridemia; PhysiotensTM, for the treatment of hypertension; and SynthroidTM, for the treatment of hypothyroidism; • pain and central nervous system products, including SercTM, for the treatment of Ménière’s disease and vestibular vertigo; BrufenTM, for the treatment of pain, fever, and inflammation; and SevedolTM, for the treatment of severe migraines; • respiratory drugs and vaccines, including the anti-infective clarithromycin (sold under the trademarks KlacidTM, ClaribidTM, and KlaricidTM); and InfluvacTM, an influenza vaccine; and • biologic products, which include biosimilars in the areas of oncology, immunology, and women's health. The Established Pharmaceutical Products segment directs its primary marketing efforts toward building strong brands with key stakeholders, including consumers, pharmacists, physicians, and other healthcare providers. Government agencies are also important customers. ________________________________________________________ * As used throughout the text of this report on Form 10-K, the term “Abbott” refers to Abbott Laboratories, an Illinois corporation, or Abbott Laboratories and its consolidated subsidiaries, as the context requires. 1 Table of Contents Competition in the Established Pharmaceutical Products segment is generally from other healthcare and pharmaceutical companies. In addition, the substitution of generic drugs for the brand prescribed and introduction of additional forms of already marketed established products by generic or branded competitors may increase competitive pressures. Diagnostic Products These products include a broad line of diagnostic systems and tests manufactured, marketed, and sold worldwide. These products are generally marketed and sold directly to blood banks, hospitals, commercial laboratories, clinics, physicians’ offices, retailers, government agencies, alternate care testing sites, and plasma protein therapeutic companies from Abbott-owned distribution centers, public warehouses or third-party distributors. The principal products included in the Diagnostic Products segment are: • core laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing, including the Alinity ® family of instruments along with the ARCHITECT ® and Cell-Dyn ® systems. These systems are used for screening and/or diagnosis for cancer, cardiac and metabolic disorders, drugs of abuse, thyroid function, fertility, neurologic and general chemistries, infectious diseases such as hepatitis and HIV, therapeutic drug monitoring, and a suite of SARS-CoV-2 serology assays; • molecular diagnostics polymerase chain reaction (PCR) instrument systems, including Alinity ® m and m2000TM that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents including HIV, hepatitis, HPV, sexually transmitted infections, SARS-CoV-2 and influenza A & B, and respiratory syncytial virus (RSV); and products for oncology with the Vysis ® FISH product line of genomic-based tests; • point-of-care systems, including the i-STAT ® and i-STAT ® Alinity ® and cartridges for testing blood gas, chemistry, electrolytes, coagulation and immunoassay; • rapid diagnostics lateral flow testing products in the area of infectious diseases such as SARS-CoV-2, including the BinaxNOW ® and Panbio ® rapid testing platforms, influenza, HIV, hepatitis, and tropical diseases such as malaria and dengue fever; molecular point-of-care testing for HIV, including the m-PIMA ® HIV-1/2 Viral Load Test, and for SARS-CoV-2 and influenza A & B, RSV and strep A, including the ID NOW ® rapid molecular